Efﬁcacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Narisa Ruenroengbun1, Tunlanut Sapankaew2, Kamolpat Chaiyakittisopon3, Pakpoom Phoompoung4 and Thundon Ngamprasertchai5*

1 Department of Pharmaceutics (Clinical Pharmacy), Faculty of Pharmacy, Silpakorn University, Nakonprathom, Thailand, 2 Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand, 3 Department of Community Pharmacy and Administrations, Faculty of Pharmacy, Silpakorn University, Nakonprathom, Thailand, 4 Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 5 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Many antiviral agents have been studied in clinical trials for allograft rejection prevention following cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients. However, data on the most effective and safest treatment are lacking. We conducted a systematic review and network meta-analysis to rank CMV prophylaxis agents for allograft rejection prevention following CMV prophylaxis in high-risk kidney transplant patients according to their efﬁcacy and safety. We conducted searches on the MEDLINE, Embase, SCOPUS, and CENTRAL databases, as well as the reference lists of selected studies up to December 2021, for published and peer-reviewed randomized controlled trials assessing the efﬁcacy of CMV prophylaxis agents in high-risk kidney transplant patients. Thirteen studies were independently selected by three reviewers and included post-kidney transplant patients indicated for CMV prophylaxis who had been randomized to receive prophylactic antiviral agents or standard of care. The reviewers independently extracted data from the included studies, and direct and network meta-analyses were applied to assess the study outcomes. The probability of efﬁcacy and safety was evaluated, and the drugs were assigned a numerical ranking. We evaluated the risk of bias using the Cochrane Risk of Bias 2.0 tool. The primary outcome was an incidence of biopsy-proven acute rejection, whereas the secondary outcome was a composite of major adverse drug reactions. Each outcome referred to the deﬁnition provided in the original studies. Valganciclovir, valacyclovir, and ganciclovir were identiﬁed to signiﬁcantly decrease the incidence of biopsy-proven acute rejection with pooled risk differences (RDs) of −20.53% (95% conﬁdence interval [CI] = −36.09% to −4.98%), −19.3% (95% CI = −32.7% to
INTRODUCTION

Even though kidney transplantation (KT) has increased survival in end-stage renal disease (Abecassis et al., 2008), infectious complications following KT have resulted in suboptimal outcomes, thus contributing to morbidity and mortality (Noppakun et al., 2015). Cytomegalovirus (CMV) is the leading cause of infectious etiologies resulting in high mortality (Razonable and Humar, 2019). The CMV disease spectrum ranges from asymptomatic infection to symptomatic CMV syndrome or invasive CMV disease. CMV infection in KT not only has a direct impact on targeted organs but also indirectly increases the risk for allograft rejection and other opportunistic infections (Ramanan and Razonable, 2013). CMV infection also indirectly stimulates adhesion and induces transforming growth factor (TGF)-β production, which leads to fibrogenesis (Helantera et al., 2003). Therefore, patients with CMV infection have a higher risk of allograft failure and death (Watcharananan et al., 2012; Raval et al., 2021). In a Thai study, the prevalence of asymptomatic CMV infection and CMV disease among KT recipients were 5%–21% and 7%, respectively (Watcharananan et al., 2012; Chiasakul et al., 2015). Older recipients receiving organs from CMV-seropositive donors or induction with anti-thymocyte globulin or lymphocyte-depleting agents were associated with CMV infection. Nearly all Thai donors and recipients were CMV seropositive, which indicates a moderate risk of CMV infection (Watcharananan et al., 2012; Chiasakul et al., 2015).

Prevention strategies against CMV infection vary among transplant centers in Thailand. A recent nationwide survey showed that almost 80% of Thai physicians implemented prevention strategies, including preemptive approaches (48%) and prophylaxis (45%). Prophylaxis is preferred for high-risk patients, such as those with a high level of immunosuppression (Bruminhent et al., 2019).

Currently, several antiviral agents are indicated for CMV prophylaxis against allograft rejection following KT, namely, valganciclovir (VGC), ganciclovir (GC), valacyclovir (VAC), and acyclovir (AC). The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend oral GC or VGC for CMV prophylaxis (Kasiske et al., 2010). VAC and AC are prescribed for CMV prophylaxis in current clinical practice (Kacer et al., 2015; Stamps et al., 2021). However, some drugs are not easily accessible in low- to middle-income countries. Additionally, VGC is expensive and is thus seldom used in general hospitals. However, KT has been increasingly performed in general hospitals in Thailand.

To our knowledge, previous systematic reviews and meta-analyses on CMV prophylaxis following KT have focused on the direct effects of antiviral agents on CMV infections, including CMV viremia or invasive CMV disease (Chatani et al., 2019; Ruenroengbun et al., 2021). The proper dosage of antiviral agents or preventive strategies in CMV prophylaxis following KT have also been reported (Florescu et al., 2014; Xin et al., 2017; Hwang et al., 2018; Lee et al., 2021). However, studies on antiviral agent efficacy against allograft rejection, as well as the relative efficacy and safety, are scarce. Therefore, we conducted a systematic review and network meta-analysis to estimate and rank the comparative efficacy and a composite of major adverse drug reactions (ADRs) of currently available antiviral agents against allograft rejection following CMV prophylaxis in high-risk patients.

METHODS

The systematic review and network meta-analysis protocol were developed following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Network Meta-Analysis extension or PRISMA-NMA. Intention-to-treat analysis was conducted for all quantitative synthesizes. The review protocol was registered with PROSPERO (CRD42019145845).

Search Strategies

We searched for potential studies on the MEDLINE via PubMed, Embase, SCOPUS, and The Cochrane Central Registry of Controlled Trials (CENTRAL) databases up to December 2021. Two investigators (N.R. and K.C.) developed search strategies that were approved by the team. The search terms and strategies for each database were generated based on the targeted population, types of antiviral agents, and outcomes. The full search strategies are available in the Supplementary Table 1.

Selection of Studies

The identified studies were independently selected on the basis of the title and abstract by two independent reviewers (N.R. and K.C.). Disagreement was resolved by discussion with a third reviewer (T.S.). Titles and abstracts were screened, and the full text was reviewed when a decision could not be made after reading the abstracts.
Inclusion Criteria
We included randomized controlled trials (RCTs) in any language when they met the following criteria:

1. Participants were adult kidney transplant recipients who received prophylactic antiviral agents for CMV infection as indicated in primary articles;
2. The studies compared any two of the following interventions: AC, GC, VC, or any placebo;
3. The primary outcome was an incidence of biopsy-proven acute rejection (BPAR), and the secondary outcome was a composite of major ADRs;
4. The full text could be retrieved, and data were available for extraction; and
5. The study was published in a peer-reviewed journal or clinical trial registry.

Studies were excluded if foscarnet was used as an antiviral agent, as it has been indicated in CMV resistance treatment or intravenous immunoglobulin-containing regimen. Additionally, studies that reported BPAR without preceding CMV infection were excluded. Ongoing studies or study protocols from which we could not extract the results were also excluded.

Data Extraction
At least two of the three reviewers (N.R., K.C, and T.S.) independently extracted data using a standardized extraction form. The extracted data included the general characteristics of the articles, population, intervention, and outcomes of interest for pooling. Discrepancies were resolved by discussion or by a fourth reviewer (T.N.). Missing data were obtained by contacting the corresponding authors email or other researchers’ network platforms such as ResearchGate, Academia or Loop.

Outcomes of Interest
The primary outcome of interest was BPAR associated with CMV infection after KT. The secondary outcome was a composite of major ADRs, including neutropenia, thrombocytopenia, leukopenia, anemia, and hallucinations.

Risk of Bias Assessment
At least two of the three reviewers (N.R., K.C, and T.S.) independently evaluated the risk of bias of each study using the Cochrane Risk of Bias 2.0 tool for RCTs. The Risk of Bias 2.0 tool evaluates five domains of bias: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported results. The risk of bias for each of the five domains and the overall risk of bias were described as low, intermediate, or high. Disagreement between two authors was resolved by consensus and discussion. Cohen’s kappa was used to determine the agreement for each domain and the overall risk of bias.

Statistical Analysis
We reported our systematic review following the PRISMA-NMA guidelines. Direct meta-analysis of comparisons between prophylactic antiviral agents for CMV infection and placebo or comparators was conducted by pooling risk difference (RD) if at least three studies were involved. The Q test and I² statistics were used to assess heterogeneity. If heterogeneity was present or the degree of heterogeneity (I²) was greater than 25%, the RDs were estimated using a random-effects model. Otherwise, a fixed-effects model was applied. We assessed publication bias using funnel plots and the Egger test.

For indirect comparisons, network meta-analysis was applied to determine the treatment effects for all possible treatment groups. A two-stage network meta-analysis was conducted to estimate the RD of all treatments using information from comparisons with common comparators to increase the power of the test by integrating direct and indirect comparisons. The consistency assumption (i.e., agreement between estimates from direct and indirect evidence) was also applied. In the comparison, AC, GC, VAC, VGC, and placebo or comparators were coded as 1, 2, 3, 4, and 0, respectively. Inconsistency was calculated as the difference between the indirect and direct estimates for a common comparator. The surface under the cumulative ranking curve (SUCRA) was used to rank the regimens in terms of efficacy and safety. A clustered ranking plot was used to present the benefits of BPAR prevention and safety according to the SUCRA. Publication bias was depicted using a comparison-adjusted funnel plot. All analyses were conducted using STATA® version 16.0 (StataCorp LP, College Station, TX, USA). A two-sided p-value of <0.05 was considered statistically significant, except in the heterogeneity test, in which a p-value of <0.1 was used.

RESULTS
Study Characteristics of Included Studies
A total of 2,461 articles were identified, of which 2,433 were found ineligible and thus excluded (Figure 1). Overall, 13 RCTs were included for analysis. Five treatments were analyzed: AC, GC, VAC, VGC, and placebo. All these trials were conducted in developed countries, mostly in North America or Europe (Table 1). The trials recruited high-risk kidney transplant patients who were placed on a CMV prophylaxis regimen and compared antiviral prophylactic agents with placebo/comparators. Most of these studies were conducted during the 20th century and mainly focused on GC, whereas oral antiviral agents were studied thereafter. The incidence of CMV infections reported, including CMV viremia or diseases following prophylactic antiviral agents, ranged from 11.7% to 90.6%. The incidence of CMV infections during the 20th century was relatively high. Follow-up time among studies mostly ranged 6–12 months. Nearly all studies implemented lymphocyte-depleting antibody therapy. We assessed the included studies according to the outcome as follows: Thirteen studies reported BPAR, and six studies examined the rates composites of major ADRs.

Risk of Bias Assessment Across the Included RCTs
The overall quality of the studies was rated as “some concerns” (Supplementary Figure 1). The highest quality was noted for the missing outcome data, whereas the lowest quality was noted for the randomization process domain.
Direct Meta-Analysis
The incidence of BPAR was reduced by approximately 20% with GC (pooled RD = −0.22; 95% confidence interval [CI] = −0.32, −0.13; p < 0.01) compared with placebo (Supplementary Figure 2). Meanwhile, AC slightly increased the incidence of BPAR, but not significantly (pooled RD = 0.04; 95% CI = −0.09, 0.18; p = 0.53; Supplementary Figure 3). No publication bias was found, as assessed by the funnel plot for these outcomes (Supplementary Figures 4, 5). Less than three studies on ADRs were conducted on each agent; therefore, we were unable to conduct a direct meta-analysis.

Network Meta-Analysis
Figure 2 presents the network of eligible comparisons for BPAR incidence following CMV infection after KT. There was no evidence of inconsistency in efficacy and major adverse drug outcomes (chi-square = 7.52, p = 0.2621 and chi-square = 1.6, p = 0.6553, respectively). Supplementary Figure 6 presents the network of eligible comparisons for the major adverse reactions.

Incidence of BPAR
Incidence of BPAR from 13 studies (n = 1,613) consisting of seven direct comparisons among five treatments was pooled. Overall, VGC, VAC, and GC showed statistically better outcomes than did placebo. VGC particularly showed the highest risk reduction than did placebo with pooled RDs of −0.21 (95% CI = −0.36, −0.05), followed by VAC and GC with pooled RDs of −0.09 (95% CI = −0.22, −0.04). The highest probability of efficacy regarding the incidence of BPAR, as indicated by the highest SUCRA, was identified for VGC, followed by VAC, GC, and AC.
### TABLE 1 | Characteristics of studies included in the review and network meta-analysis.

| Study               | N   | CMV serostatus | Interventions | Comparator | BPAR | Major Adverse Drug Reactions | CMV Infection* (%) | Follow-up time (months) | Lymphocyte-depleting antibody therapy* (%) | Maintenance immunosuppressive regimens* (%) | Countries |
|---------------------|-----|---------------|---------------|------------|------|-----------------------------|--------------------|------------------------|-------------------------------------------|---------------------------------------------|-----------|
|                     | D+ | D− | R+ | R− | D+ | D− | R+ | R− | Intervention (%) | Comparator (%) | Intervention (%) | Comparator (%) | | | |
| Balfour et al. (1989) | 104 | 31 | 43 | 30 | 0   | 0   | 0   | 0   | 15 (28.2) | 12 (23.5) | 1 (1.89) | 3 (5.88) | 57.7 | 3–12 | 8.65 | NA | USA |
| Rondeau et al. (1993) | 32  | 0   | 0   | 32 | 0   | IV Ganciclovir 5 MKD B.I.D. | Control | 10 (58.8) | 9 (60.0) | NA | NA | 75.0 | 3–12 | 18.8 | NA | France |
| Rostaing et al. (1994) | 37 | 17 | 20 | 0 | 0   | Ayclovir 800 mg Q.I.D. | Control | 7 (28.3) | 8 (30.6) | NA | NA | 64.9 | 3–12 | 100 | – | 70 | 30 | France |
| Conti et al. (1995) | 40  | 40 | 0   | 0   | Ganciclovir 2.5 MKD | Control | 8 (22.2) | 13 (36.4) | 0 (0.03) | 0 (0.00) | 35 | 12 | 95.0 | NA | USA |
| Kletzmayr et al. (1996) | 32 | 0   | 0   | 32 | 0   | Ayclovir 200–800 mg Q.I.D. | Control | 13 (39.1) | 4 (18.0) | NA | NA | 90.6 | 3–12 | NA | – | 100 | Austria |
| Ahsan et al. (1998) | 43  | 13 | 10 | 8 | 12 | Ayclovir 750 mg B.I.D. | Control | 1 (4.5) | 4 (18.2) | NA | NA | 16.3 | 6 | 11.6 | NA | USA |
| Brennan et al. (1999) | 42  | 24 | 13 | 5 | 0   | Ganciclovir 1,000 mg T.I.D. | Ayclovir | 3 (20.0) | 4 (19.0) | 3 (20.0) | 2 (9.52) | 85.7 | 3–6 | 7.14 | – | 100 | USA |
| Conti et al. (1997) | 244 | 244 | 0   | 0   | Ganciclovir 2.5 MKD B.I.D. | Control | 31 (24.6) | 58 (49.2) | NA | NA | 22.9 | 12 | NA | – | 100 | USA |
| Flechner et al. (1998) | 101 | 29 | 23 | 27 | 0   | Ganciclovir 1,000 mg T.I.D. | Ayclovir | 7 (17.9) | 13 (32.5) | NA | NA | 13.9 | 3–6 | 100 | – | 100 | USA |
| Lowrance et al. (1999) | 616 | 408 | 208 | 0   | Valacyclovir 2,000 mg Q.I.D. | Control | 107 (17.9) | 179 (30.0) | 37 (12.1) | 36 (11.6) | 32.6 | 3–6 | 16.6 | – | 81 | USA and Europe |
| Paju et al. (2004) | 120 | 0   | 0   | 120 | 0   | Valganciclovir 900 mg Q.I.D. | Ganciclovir | 17 (21.2) | 9 (23.1) | NA | NA | 11.7 | 6 | NA | NA | USA |
| Rieischg et al. (2005b) | 83  | 60 | 13 | 10 | 0   | Valganciclovir 2,000 mg Q.I.D. | Ganciclovir | 12 (22.0) | 4 (14.3) | 7 (19.0) | 7 (20.0) | 21.7 | 12 | 12.7 | 11 | 48 | – | Czech |
| Rieischg et al. (2018) | 119 | 93 | 15 | 11 | 0   | Valganciclovir 900 mg Q.I.D. | Valganciclovir 2,000 mg Q.I.D. | 8 (13.3) | 15 (25.4) | 21 (13.3) | 13 (22.0) | 35.0 | 6–36 | 50.4 | 49 | 51 | – | Czech |

| D, donor; R, recipient; BPAR, biopsy-proven acute rejection; CMV, cytomegalovirus; KT, kidney transplantation; LT, liver transplantation; N, number of total patients in study; mg, milligram; Q.I.D., once daily; B.I.D., twice a day; T.I.D., three times a day; | |
| Q.I.D., four times a day; IV, intravenous; MKD, milligram per kilogram per dose; m, month; y, year; NA, data not available. |
| CMV infection included either CMV diseases or CMV viremia. |
| Lymphocyte-depleting antibody therapy included thymoglobulin, ATG, OKT-3, or alemtuzumab. |
| All regimens contained mycophenolate mofetil and steroid. |
Safety Regarding a Composite of Major Adverse Drug Reactions

Overall, the composite of major ADRs was 5.7% without a significant difference when compared with placebo (Table 2). The relative major ADRs among the antiviral agents showed that VGC was the safest with approximately 10% fewer ADRs than comparators, whereas VAC slightly increased ADR compared with other comparators but without statistical significance (Table 3). The overall probabilities for efficacy and major ADRs were presented as cluster ranking plots (Figure 3). In terms of efficacy and low risk of ADRs, VGC was ranked highest for efficacy and safety and presented lying in the upper-right quadrant (SUCRA 84.2 and 88.5, respectively) (Supplementary Table 2). VAC was ranked second for efficacy (SUCRA 74.3) but had the highest risk for ADR (SUCRA 28.2) and indicated lying in the lower-right quadrant. Although AC and GC showed similar efficacies (SUCRA 44 and 47.3, accordingly), AC had fewer ADRs than GC.

Publication Bias of the Network

Comparison-adjusted funnel plots were applied for the incidence of BPAR. No evidence of publication bias was found based on the symmetry of the funnel plot (Supplementary Figure 7).

DISCUSSION

Our systematic review revealed that antiviral agents contributed to the incidence of BPAR reduction which supported the benefit of antiviral agents to reduce the indirect effect of CMV on allograft failure (Watcharananan et al., 2012; Raval et al., 2021). Compared with placebo, GC reduced the incidence of BPAR following CMV prophylaxis in high-risk patients. Minimal increased incidence of BPAR was observed with AC. This is because AC confers no benefits on CMV infection and disease. This finding was consistent with previous studies (Rubin et al., 2000; Hodson et al., 2008; Ruenroengbun et al., 2021).
VGC showed the best comparative efficacy for allograft rejection prevention after CMV prophylaxis, followed by VAC and GC. VGC also had a lower pill burden than VAC and GC. Since high-risk recipients must undergo a CMV prophylaxis regimen for at least 3 months, compliance with the regimen should be considered. The pharmacokinetics of antiviral agents is another factor determining the optimal outcome. Given the high bioavailability of VGC, it demonstrated a 10-fold higher bioavailability than oral GC (Lake, 2003) and was as equally effective as oral GC in preventing CMV infection in solid-organ transplantation (Paya et al., 2004). It is also recommended in clinical practice guidelines (Kasiske et al., 2010). Similarly, VAC has a threefold to fivefold higher oral bioavailability than oral AC (Soul-Lawton et al., 1995). Several reports found that VAC was as effective as oral GC following KT (Reischig et al., 2002; Pavlopoulou et al., 2005; Reischig et al., 2005a). Most of the indicated Thai patients receive intravenous (IV) GC as a result of poor bioavailability of oral GC and inaccessibility to oral VGC as a financial problem. However, CMV prophylaxis requires a long treatment duration of antiviral agents. Therefore, some patients

### TABLE 3 | Results of the network meta-analysis of the incidence of BPAR and major ADR.

| Interventions | Comparators | BPAR | MajorADR | Intervention | Comparators | BPAR | MajorADR |
|---------------|-------------|------|----------|-------------|-------------|------|----------|
| AC            | PC          | 0.04 | −0.04    | VAC         | PC          | −0.19| 0.00     |
|               |             | (−0.09, 0.18) | (−0.11, 0.03) |             | (−0.33, −0.06) | (−0.05, 0.05) |
| GC            | 0.02        | −0.04|          | AC          | −0.11       |      | 0.04     |
|               | (−0.13, 0.16) | (−0.14, 0.06) |             | (−0.29, 0.08) | (−0.04, 0.13) |
| VAC           | 0.11        | −0.04|          | GC          | −0.09       | 0.01 |         |
|               | (−0.08, 0.29) | (−0.13, 0.04) |             | (−0.22, −0.04) | (−0.07, 0.09) |
| VGC           | 0.12        | 0.07 |          | VGC         | 0.01        | 0.11 |         |
|               | (−0.08, 0.32) | (−0.11, 0.25) |             | (−0.13, 0.15) | (−0.06, 0.29) |
| GC            | PC          | −0.10| 0.01     | VGC         | −0.21       |      | −0.11    |
|               | (−0.20, −0.01) | (−0.08, 0.07) |             | (−0.36, −0.05) | (−0.29, 0.06) |
| AC            | −0.02       | 0.04 |          | AC          | −0.12       | 0.07 |         |
|               | (−0.16, 0.13) | (−0.06, 0.13) |             | (−0.32, 0.08) | (−0.25, 0.11) |
| VAC           | 0.09        | −0.00|          | GC          | −0.10       | 0.11 |         |
|               | (−0.04, 0.22) | (−0.09, 0.08) |             | (−0.24, 0.04) | (−0.27, 0.04) |
| VGC           | 0.10        | 0.11 |          | VAC         | −0.01       | −0.11|         |
|               | (−0.04, 0.24) | (−0.04, 0.27) |             | (−0.15, 0.13) | (−0.29, 0.06) |

BPAR, biopsy-proven graft rejection; ADR, adverse drug reaction; NA, not applicable; AC, acyclovir; GC, ganciclovir; VAC, valacyclovir; VGC, valganciclovir.

FIGURE 3 | Cluster ranking plot of antiviral agents showing their surface under the cumulative ranking curve (SUCRA) values for the highest probability of incidence of biopsy-proven acute rejection (BPAR) versus SUCRA values for the lowest probability of major adverse drug reactions (ADRs). Each square point represents a group of antiviral agents in each cluster. Antiviral agents lying in the upper-right corner are associated with a higher probability of incidence of BPAR and a lower probability of major ADRs.
are unable to tolerate IV GC. Additionally, VGC is rarely used in general hospitals, despite the gradual increase in KTIs performed in these hospitals.

Our findings suggest that VAC would be a feasible alternative antiviral treatment for CMV prophylaxis in high-risk KT recipients. Nevertheless, higher dosage (8 g/day) was used in the aforementioned studies. High pill burden and neurotoxicity might limit its use in clinical practice. Consequently, compliance and dose-related toxicities should be closely monitored. In addition, current guidelines are not convincing regarding using VAC. Physicians should avoid AC for CMV prophylaxis, as its antiviral activities are ineffective against CMV infection. Moreover, minimal increased risk of BPAR were observed in AC group.

When the composite of major drug reactions was considered, VGC was ranked first for safety, followed by AC, GC, and VAC. Our findings thus support VGC recommendations in current guidelines in terms of efficacy and safety. Even though AC is safe, physicians should avoid its use because of its poor efficacy. The safety of GC was similar to that of VAC. We recommend VAC over GC in the Thai clinical setting for the aforementioned reason or for patients who are unable to tolerate GCV.

Our study has several strengths. First, we ranked the efficacy of antiviral agents on allograft rejection outcome. As this outcome determines survival of KT recipients. Second, the results have high generalizability and are highly applicable in low- to middle-income countries where VGC is not widely available. Lastly, we included the variety of CMV serostatus among donors and recipients which were generalized to both low and high-risk populations. However, this study has some limitations. The included studies presented heterogeneity regarding dosage and route administration of antiviral agents. Additionally, Other types of allograft rejection outcome, such as antibody-mediated rejection, were limited since most included studies were published before 2000. Finally, further large-scale and well-conducted RCTs are needed.

Overall, VGC was the best antiviral agent identified in terms of both efficacy and safety for allograft rejection prevention following CMV prophylaxis. VAC was identified as an optimal alternative for patients who are unable to tolerate GC or when oral GC is unavailable.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

Substantially contributed to conception or design: NR and TN. Contributed to identified and extracted data: NR, TS, and KC. Contributed to analysis, or interpretation of data: NR, TS, and KC. Drafted the manuscript for important content: NR and TN. Critically reviewed the manuscript for important intellectual content: PP and TN. All authors contributed to the article and approved the submitted version.

FUNDING

No sponsorship for this study. The publication fee was funded by Faculty of Tropical Medicine, Mahidol University and Mahidol University, Bangkok, Thailand.

ACKNOWLEDGMENTS

The authors also would like to thank Enago™ (http://www.enago.com/) for the English language review. Supported for this assistance was funded by Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2022.865735/full#supplementary-material

REFERENCES

Abecassis, M., Bartlett, S. T., Collins, A. I., Davis, C. L., Delmonico, F. L., Friedewald, J. J., et al. (2008). Kidney Transplantation as Primary Therapy for End-Stage Renal Disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI) Conference. Clin. J. Am. Soc. Nephrol. 3 (2), 471–480. doi: 10.2215/cjn.05021107

Ahsan, N., Holman, M. J., Sonderbye, L., Langhoff, E., and Yang, H. C. (1998). Oral Ganciclovir in the Prevention of Cytomegalovirus Infection in Postkidney Transplant “CMV at Risk” Recipients: A Controlled, Comparative Study of Two Regimens (750 Mg Bid and 500 Mg Bid). Transplant. Proc. 30 (4), 1383–1385. doi: 10.1016/s0041-1345(98)00283-8

Balfour, H. H., Jr., Chace, B. A., Stapleton, J. T., Simmons, R. L., and Fryd, D. S. (1989). A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts. N. Engl. J. Med. 320 (21), 1381–1387. doi: 10.1056/nejm198905253202105

Brennan, D. C., Garlock, K. A., Lippmann, B. A., Buller, R. S., Gaudeult-Keener, M., Lowell, J. A., et al. (1997). Control of Cytomegalovirus-Associated Morbidity in Renal Transplant Patients Using Intensive Monitoring and Either Preemptive or Deferred Therapy. J. Am. Soc. Nephrol. 8 (1), 118. doi: 10.1668/ASN.V81118

Brumminhent, J., Bushyananist, A., Kantachueviri, S., and Kiertiburanakul, S. (2019). A Nationwide Survey of Cytomegalovirus Prevention Strategies in Kidney Transplant Recipients in a Resource-Limited Setting. Open Forum Infect. Dis. 6 (9), ofz322. doi: 10.1093/ofid/ofz322

Chatani, B., Glaberson, W., Nemeth, Z., Tamariz, L., and Gonzalez, I. A. (2019). GCV/VCVG Prophylaxis Against CMV DNAemia in Pediatric Renal Transplant Patients: A Systematic Review and Meta-Analysis. Pediatr. Transplant. 23 (6), e13514. doi: 10.1111/petr.13514

Chiasakul, T., Townmachi, N., Jutivorakool, K., Chanchoreonthana, W., Thongprayoon, C., Watanatorn, S., et al. (2015). Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand. Transplant. Proc. 47 (8), 2460–2464. doi: 10.1016/j.transproceed.2015.08.011

Conti, D. J., Freed, B. M., Singh, T. P., Gallichio, M., Gruber, S. A., and Lempert, N. (1995). Preemptive Ganciclovir Therapy in Cytomegalovirus-Seropositive Renal Transplant Recipients. Arch. Surg. 130 (11), 1217–1221; discussion 1221-1212. doi: 10.1001/archsurg.1995.01430110075014
Conti, D. J., Shen, G., Singh, T., Isenberg, A., and Freed, B. M. (1997). Ganciclovir Prophylaxis of Cytomegalovirus Disease. Transplant. Proc. 29 (1-2), 804–806. doi: 10.1016/S0041-1345(96)00141-8

Flechner, S. M., Avery, R. K., Fisher, R., Mastroianni, B. A., Papacik, D. A., O’Malley, K. J., et al. (1998). A Randomized Prospective Controlled Trial of Oral Acyclovir Versus Oral Ganciclovir for Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients. Transplantation 66 (12), 1682–1688. doi: 10.1097/00007890-199812270-00019

Florescu, D. F., Qiu, F., Schmidt, C. M., and Kalil, A. C. (2014). A Direct and Indirect Comparison Meta-Analysis on the Efficacy of Cytomegalovirus Preventive Strategies in Solid Organ Transplant. Clin. Infect. Dis. 58 (6), 785–803. doi: 10.1093/cid/ciu485

Helantera, I., Koskinen, P., Tornroth, T., Logинov, R., Gronhagen-Riska, C., and Lautenschlager, I. (2003). The Impact of Cytomegalovirus Infections and Acute Rejection Episodes on the Development of Vascular Changes in 6-Month Protocol Biopsy Specimens of Cadaveric Kidney Allograft Recipients. Transplantation 75 (11), 1858–1864. doi: 10.1097/01.Tp.0000064709.20841.E1

Hodson, E. M., Craig, J. C., Strippoli, G. F., and Webster, A. C. (2008). Antiviral Medications for Preventing Cytomegalovirus Disease in Solid Organ Transplant Recipients. Cochrane Database Syst. Rev. 2, CD003774. doi: 10.1002/14651858.CD003774.pub3

Hwang, S. D., Lee, J. H., Lee, W. S., Kim, J. K., Kim, J. M., and Song, J. H. (2018). Effect of Low-Dose Vs Standard-Dose Valganciclovir in the Prevention of Cytomegalovirus Disease in Kidney Transplantation Recipients: A Systematic Review and Meta-Analysis. Transplant. Proc. 50 (8), 2473–2478. doi: 10.1016/j.tranpro.2018.01.023

Kacer, M., Kiellmmer, L., Bouda, M., and Reischig, T. (2015). Valganciclovir Versus Valacyclovir Prophylaxis for Prevention of Cytomegalovirus: An Economic Perspective. Transpl. Infect. Dis. 17 (3), 334–341. doi: 10.1111/tid.12383

Kasiske, B. L., Zeiger, M. G., Chapman, J. R., Craig, J. C., Elckberg, H., Garvey, C. A., et al. (2010). KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients: A Summary. Kidney Int. 77 (4), 299–311. doi: 10.1038/ki.2009.377

Kletzmayr, J., Kotzmann, H., Popow-Kraupp, T., Kovarik, J., and Klausner, R. (1996). Impact of High-Dose Oral Acyclovir Prophylaxis on Cytomegalovirus (CMV) Disease in CMV-High-Risk Renal Transplant Recipients. J. Am. Soc. Nephrol. 7 (2), 325–330. doi: 10.1681/asn.V72325

Lake, K. D. (2003). New Prophylactic Treatment Strategy for Cytomegalovirus Disease. Am. J. Health Syst. Pharm. 60 (23 Suppl S8), S13–S16. doi: 10.1001/jhap.60.sup1.SS13

Lee, J. H., Lee, L., Lee, S. W., Hwang, S. D., and Song, J. H. (2021). Efficacy and Safety According to the Dose of Valganciclovir for Cytomegalovirus Prophylaxis in Transplantation: Network Meta-Analysis Using Recent Data. Transplant. Proc. 53 (6), 1945–1950. doi: 10.1016/j.transproceed.2021.05.006

Lowance, D., Neumayer, H.-H., Legendre, C. M., Squilliet, J.-F., Kovarik, J., Brennan, P. J., et al. (1999). Valacyclovir for the Prevention of Cytomegalovirus Disease After Renal Kidney Transplantation. New Engl. J. Med. 340 (19), 1462–1470. doi: 10.1056/NEJM199905133401903

Noppakan, K., Ingathit, A., Pongskul, C., Premasthan, N., Avihingsanon, Y., Lumpsaeng, A., et al. (2015). A 25-Year Experience of Kidney Transplantation in Thailand: Report From the Thai Transplant Registry. Nephrol. (Carlton) 20 (3), 177–183. doi: 10.1111/dep.12378

Pavlopoulos, I. D., Syriopoulos, V. P., Chelioti, H., Dakos, G. L., Stamatides, D., Kostakis, A., et al. (2005). A Comparative Randomised Study of Valacyclovir vs. Oral Ganciclovir for Cytomegalovirus Prophylaxis in Renal Transplant Recipients. Clin. Microbiol. Infect. 11 (9), 736–743. doi: 10.1111/j.1469-0691.2005.01215.x

Paya, C., Humar, A., Domínguez, E., Washburn, K., Blumberg, E., Alexander, B., et al. (2004). Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients. Am. J. Transplant. 4 (4), 611–620. doi: 10.1111/j.1600-6143.2004.00382.x

Raman, P., and Razonable, R. R. (2013). Cytomegalovirus Infections in Solid Organ Transplantation: A Review. Infect. Chemother. 45 (3), 260–271. doi: 10.3947/ic.2013.45.3.260

Raval, A. D., Kistler, K. D., Tang, Y., Murata, Y., and Snydman, D. R. (2021). Epidemiology, Risk Factors, and Outcomes Associated With Cytomegalovirus in Adult Kidney Transplant Recipients: A Systematic Literature Review of Real-World Cytomegalovirus Disease. Transplant. Int. 33 (2), e13483. doi: 10.1111/tid.13483

Razonable, R. R., and Humar, A. (2019). Cytomegalovirus in Solid Organ Transplant Recipients: Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transplant. 33 (9), e13512. doi: 10.1111/citr.13512

Reischig, T., Jindra, P., Mares, J., Cechura, M., Svecova, M., Hes, O., et al. (2005a). Valacyclovir for Cytomegalovirus Prophylaxis Reduces the Risk of Acute Renal Allograft Rejection. Transplantation 79 (3), 317–324. doi: 10.1097/01.tp.0000150024.01672.ca

Reischig, T., Kacer, M., Hrubá, P., Hermanova, H., Hes, O., Lysak, D., et al. (2018). Less Renal Allograft Fibrosis With Valganciclovir Prophylaxis for Cytomegalovirus Compared to High-Dose Valacyclovir: A Parallel Group, Open-Label, Randomized Controlled Trial. BMC Infect. Dis. 18 (1), 573. doi: 10.1186/s12879-018-3493-y

Reischig, T., Opatrný, K., Jr., Bouda, M., Treska, V., Jindra, P., and Svecova, M. (2002). A Randomized Prospective Controlled Trial of Oral Ganciclovir Versus Oral Valganciclovir for Prophylaxis of Cytomegalovirus Disease After Renal Transplantation. Transpl. Int. 15 (12), 615–622. doi: 10.1007/s00475-002-0475-0

Rubin, R. H., Kemmerly, S. A., Conti, D., Doran, M., Murray, B. M., Neylan, J. F., et al. (2004). Effect of Primary Cytomegalovirus Disease in Organs Transplant Recipients With Oral Ganciclovir or Oral Acyclovir Prophylaxis. Transpl. Infect. Dis. 2 (3), 112–117. doi: 10.1111/j.1399-3662.2003.00303.x

Stamps, H., Linder, K., O’Sullivan, D. M., Serrano, O. K., Rochon, C., Ebitcglu, Z., et al. (2021). Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction. Transplant. Infect. Dis. 23 (4), e15373. doi: 10.1111/tid.13577

Copyright © 2022 Ruenroengbun, Sapankaew, Chaiyakkittisopon, Phoompung and Ngamprasertchai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.